Researcher.Life Logo

Expert Opinion on Drug Metabolism and Toxicology : Impact Factor & More

eISSN: 1744-7607pISSN: 1742-5255

Aims and Scope of Expert Opinion on Drug Metabolism and Toxicology

Expert Opinion on Drug Metabolism & Toxicology is a monthly peer-reviewed medical journal publishing review articles on ADME-Tox. It was established in 2005 and is published by Taylor and Francis. The editor-in-chief is Luis Valerio (Food and Drug Administration). Less

Key Metrics

CiteScore
7.2
Eigenfactor
0.005 - 0.01
Impact Factor
< 5
SJR
Q1Toxicology
SNIP
1.21
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Expert Opinion on Drug Metabolism and Toxicology

Expert Opinion on Drug Metabolism and Toxicology Journal Specifications

Overview
Publisher TAYLOR & FRANCIS LTD
Language English
Frequency Monthly
General Details
LanguageEnglish
FrequencyMonthly
Publication Start Year2005
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Expert Opinion on Drug Metabolism and Toxicology ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Expert Opinion on Drug Metabolism and Toxicology

New insights into the role of CYP26 in retinoic acid clearance
  • 4 May 2026
  • Expert Opinion on Drug Metabolism & Toxicology
Post-marketing pharmacovigilance of tedizolid: emerging safety signals
  • 18 Apr 2026
  • Expert Opinion on Drug Metabolism & Toxicology
Impact of green tea on pharmacokinetics in cardiovascular therapy: current insights
  • 9 Apr 2026
  • Expert Opinion on Drug Metabolism & Toxicology
Substrate-specificity of pharmacogenomic variability – clinical relevance and emerging predictive strategies
  • 4 Apr 2026
  • Expert Opinion on Drug Metabolism & Toxicology
Pregnancy and epilepsy: pharmacokinetic insights into antiseizure medications
  • 3 Apr 2026
  • Expert Opinion on Drug Metabolism & Toxicology
ADME investigations of novel therapeutic modalities: challenges and opportunities 2025
  • 2 Apr 2026
  • Expert Opinion on Drug Metabolism & Toxicology
New insights into the role of CYP26 in retinoic acid clearance
  • 4 May 2026
  • Expert Opinion on Drug Metabolism & Toxicology
Post-marketing pharmacovigilance of tedizolid: emerging safety signals
  • 18 Apr 2026
  • Expert Opinion on Drug Metabolism & Toxicology
Impact of green tea on pharmacokinetics in cardiovascular therapy: current insights
  • 9 Apr 2026
  • Expert Opinion on Drug Metabolism & Toxicology
Substrate-specificity of pharmacogenomic variability – clinical relevance and emerging predictive strategies
  • 4 Apr 2026
  • Expert Opinion on Drug Metabolism & Toxicology
Pregnancy and epilepsy: pharmacokinetic insights into antiseizure medications
  • 3 Apr 2026
  • Expert Opinion on Drug Metabolism & Toxicology
ADME investigations of novel therapeutic modalities: challenges and opportunities 2025
  • 2 Apr 2026
  • Expert Opinion on Drug Metabolism & Toxicology

FAQs on Expert Opinion on Drug Metabolism and Toxicology